Full-Time
Regulatory Affairs Specialist
Brenntag
10,001+ employees
Global distributor of chemicals and logistics
No salary listed
Valencia, Spain + 1 more
More locations: Sant Cugat del Vallès, Barcelona, Spain
In Person
On-site in Spain (Barcelona or Valencia); occasional travel for meetings/audits.
Bachelor's
 Legal & Compliance (1) |
|---|
Get referred to Brenntag
See people who can refer or advise you
- Degree in a life science discipline (chemistry, biochemistry, pharmaceutical sciences) or equivalent relevant experience
- Strong knowledge of pharmaceutical industry requirements for APIs, excipients, biopharma materials, and traditional pharma raw materials
- Understanding of European National Competent Authority requirements for distribution of APIs, excipients, and raw materials
- Fluent in English and Spanish (spoken and written)
- Strong written communication skills with the ability to produce clear, accurate, and compliant documentation
- Excellent collaboration skills with the ability to work proactively across all levels and functions
- Ability to interpret regulations, resolve compliance issues, and respond to complex regulatory queries
- High attention to detail and strong organisational skills
- Willingness to undertake occasional travel for customer meetings, supplier visits, audits, or internal workshops
- Prepare, review, and issue technical and regulatory documentation required by pharmaceutical customers, including Quality and Technical Agreements, Supply Chain Statements, Regulatory Questionnaires, and Compliance Statements (e.g., TSE/BSE, GMO, allergens, nitrosamines, residual solvents, elemental impurities)
- Ensure all documentation is accurate, consistent and aligned with applicable frameworks (relevant pharmacopoeia, IPEC Guidelines, EU GDP and GMP guidelines)
- Source regulatory, quality, and technical information internally and from suppliers to fulfil customer requests
- Evaluate supplier documentation for completeness, compliance, and suitability for pharmaceutical use
- Log, track, and report customer documentation requests using defined KPIs
- Support continuous improvement by identifying trends, gaps, and opportunities to streamline documentation processes
- Lead and manage regulatory deliverables for customer-specific projects
- Coordinate regulatory assessments, supplier data collection, and compliance documentation for new product introductions or customised specifications
- Support change control evaluations and customer notifications
- Work with QHSE and supply chain teams to ensure compliance with applicable standards (IPEC GMP/GDP, EXCiPACT, GDP, and other regulatory frameworks)
- Support implementation of new regulatory requirements and internal standards across the business unit
- Partner with commercial and value-added services teams to provide regulatory expertise for customer projects and commercial initiatives
- Contribute to global Pharma Regulatory team projects, harmonisation efforts, and continuous improvement activities
- Deliver training to commercial, supply chain, and internal teams on regulatory topics relevant to supply of materials into the pharmaceutical industry
- Act as a subject matter expert for documentation, compliance, and regulatory expectations
- Perform any other tasks within capability to support the commercial, regulatory, and compliance success of the Pharma business unit
Brenntag is a global chemical distributor that connects manufacturers with users. It offers distribution, logistics, and value-added services to move chemicals efficiently across a broad network. The company differentiates itself with a large global reach and a wide range of supply-chain services that emphasize efficiency, sustainability, and transparency. Its goal is to help manufacturers reach target markets and ensure customers receive chemicals reliably while maintaining responsible and accountable operations.
Company Size
10,001+
Company Stage
IPO
Headquarters
Mülheim an der Ruhr, Germany
Founded
1874
Get referred to Brenntag
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 11% to EUR 4.3 billion, with EBITDA up 41%.
- Brenntag raised 2026 EBITDA guidance to EUR 1.35-1.45 billion after strong pricing.
- Cost-out savings hit EUR 41 million in Q2 2026, supporting margin expansion.
What critics are saying
- North Carolina sued Brenntag on June 9, 2026, over Durham water contamination.
- City fines reached $157,000 since 2023, and the discharge dispute continues unresolved.
- If environmental liabilities spread across sites, Brenntag's license-to-operate and customer trust erode quickly.
What makes Brenntag unique
- Brenntag combines global chemicals distribution with technical regulatory support and local formulation expertise.
- BYPHAR, launched July 2026, packages biopharma raw materials with documentation and GMP tiers.
- Exclusive Cargill Beauty Mexico and Woojin Korea deals deepen specialty distribution and market access.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid parental leave
Education assistance program
Employee assistance program
Health Insurance
Dental Insurance
401(k) Company Match
401(k) Retirement Plan
Flexible Work Hours
Gym/Wellness subsidy
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 8%1 year growth
↑ 8%2 year growth
↑ 8%Brenntag signs exclusive agreement with Cargill Beauty in Mexico. Brenntag Personal Care enters exclusive agreement with Cargill for distribution of its Beauty ingredients and solutions in Mexico. * New agreement expands Brenntag's Beauty & Personal Care portfolio in Mexico, providing access to Cargill's high-quality, nature-derived solutions for skin care, hair care, color care and oral care formulations * Strategic collaboration strengthens supply chain reliability alongside solutions that address evolving consumer preferences for performance and sustainability Brenntag, the global market leader in chemicals and ingredients distribution, announced today it has formalized a strategic distribution agreement with Cargill for the Mexican Personal Care market. Through this exclusive agreement, Brenntag will supply Mexico customers with the Cargill Beauty portfolio, which supports skincare, haircare and cosmetic applications with an emphasis on performance, innovation and sustainability. Cargill Beauty, the personal care division of Cargill, offers a diverse portfolio of nature-derived ingredients for personal care products. This strategic relationship expands on the established global relationships Brenntag and Cargill collaborate on. The agreement further extends Brenntag's Beauty & Personal Care portfolio in Mexico, providing customers with access to Cargill's high-quality ingredients and innovative solutions for personal care and cosmetic formulations. By combining Cargill's ingredient expertise with Brenntag's strong distribution network, technical support, and market knowledge, customers benefit from enhanced formulation capabilities, a reliable supply chain, and solutions that help address evolving consumer preferences for performance, sustainability and naturally derived products. Maia Navarrete, Senior Director Beauty & Care for Brenntag Specialties North America, commented: "We are delighted to start a relationship with Cargill Beauty and bring their innovative portfolio to customers across Mexico. This new distribution representation reinforces Brenntag Specialties Beauty & Personal Care's commitment to delivering differentiated solutions, technical expertise and innovation that help our customers meet evolving consumer needs. Together with Cargill Beauty, we look forward to creating value and accelerating growth in the Personal Care market." "We are thrilled to join forces with Brenntag, a global leader that shares our core values and vision for the future. This strategic partnership represents a powerful step forward in accelerating our business growth. By combining our strengths, we will elevate our customer focus and deliver innovative, high-performance solutions. Together, we are deeply dedicated to advancing sustainability and driving excellence in the beauty industry," added Delrika Curry, Regional Sales Director, Cargill. About Cargill Beauty: Cargill Beauty, the personal care division of Cargill, offers a diverse portfolio of nature-derived ingredients, an integrated and responsible supply chain, state-of-the-art research and application services and endless possibilities to support the sustainable growth of personal care brands. Its portfolio is composed of texturizers, emollients, emulsifiers, sensory enhancers and bio-actives to develop nature-derived products for skin care, hair care, color care and oral care. For more information, visit https://www.cargill.com/personal-care/beauty Downloads.
Brenntag Q2 2026 financial results. Brenntag delivers strong Q2 2026 results, reflecting structural improvements and disciplined execution in favourable market conditions. * Sales of EUR 4.3 billion (+11%**); Operating Gross Profit of EUR 1,146 million (+19%**); Operating EBITDA of EUR 463 million (+41%**); Gross margin increase to 26.9% (+1.7pp); EUR 41 million in cost-out savings in Q2 2026 * Sales focus and organisational simplification yield tangible results with increased customer figures and expanded key account scopes * Operating EBITDA guidance raised to range of 1,350 million - 1,450 million EUR for the full year 2026 Brenntag SE (ISIN DE000A1DAHH0), the global market leader in chemicals and ingredients distribution, today published its financial results for the second quarter of 2026. The conflict in the Middle East drove global supply chain pressure and higher pricing across chemicals markets. In this environment, Brenntag leveraged its global network, supply chain capabilities and commercial discipline to maintain reliable customer supply, while continuing disciplined execution of its key priorities and delivering tangible results. Jens Birgersson, Chief Executive Officer of Brenntag SE: "The second quarter demonstrated the strength of its business model and its more agile organization. As the conflict in the Middle East affects global chemical markets, its teams kept supply flowing and supported its customers without interruption. While performance in the first quarter 2026 was primarily driven by market volatility, a proof point of its resilient business model, its Q2 results now reflect the growing impact of its own commercial execution, improved customer penetration, pricing discipline, cost reductions and commercial excellence rather than market volatility alone. While visibility remains limited and macroeconomic uncertainty persists, Brenntag Group is increasingly confident in the direction of the business, which is also reflected in its guidance increase. Brenntag Group remain focused on operational discipline, commercial agility, and protecting profitability as visibility evolves." Financial performance In the second quarter of 2026, Brenntag generated sales of EUR 4.3 billion, up 11% year-on-year. Operating gross profit reached EUR 1,146 million (+19%**), and the gross margin expanded 1.7 percentage points to 26.9%. Operating EBITDA reached EUR 463 million (+41%**), benefiting from higher chemical pricing while volumes remained stable. The ongoing cost-out program contributed EUR 41 million in savings during the quarter versus the 2025 baseline. Free Cash Flow was EUR 4 million (Q2 2025: EUR 154 million). This decline was technical in nature, reflecting higher working capital requirements from strong sales growth and the revaluation of inventory at higher prices, rather than any increase in underlying inventory volumes. Net working capital turnover improved to 7.5x. Thomas Reisten, Chief Financial Officer of Brenntag SE: "Its cost-out program contributed EUR 41 million in savings during the quarter and is tracking in line with its full-year targets. Brenntag Group remain on course to deliver EUR 200-250 million in savings by 2027 despite temporary headwinds from higher transport and energy costs as well as bonus provisions. Free Cash Flow was temporarily impacted by higher working capital in the elevated pricing environment, which Brenntag Group continue to manage actively. At the same time, Brenntag Group improved net working capital turnover to 7.5x, confirming that working capital efficiency is moving in the right direction. Brenntag's financial position remains robust, providing the operational and financial flexibility to pursue disciplined, value-accretive bolt-on M&A and to execute on its key priorities. Based on the strong performance year-to-date, Brenntag Group has increased its operating EBITDA outlook to a range of 1,350 million - 1,450 million EUR for the full year 2026." Divisional performance Brenntag Essentials reported operating gross profit of EUR 836 million (+23.1%**), with gross margins expanding to 28.5% (+2.2 pp). As pricing rose across regions, North America and EMEA capitalized on unified pricing strategies and stocking decisions, while APAC passed on rising transportation costs as chemical prices adjusted across markets and industries. Latin America also delivered strong results. Brenntag Specialties reported operating gross profit of EUR 310 million (+8.8%**), with gross margins improving to 23.4% (+0.6 pp). Although the Middle East conflict affected Specialties less, all business units converted market opportunities into organic EBITDA growth. Especially Beauty & Personal Care and Material Science delivered strong results globally, while expanding partnerships with key principals across product groups and regions in both Life Science and Material Science. Progress on key priorities Brenntag continues to make progress on its key priorities, with commercial initiatives and organisational simplification increasingly supporting operational performance across the Group. North America captured or reactivated hundreds of customer accounts and enabled industry-focused sales teams to offer Brenntag's full portfolio. Strategic sourcing delivered supply advantages in APAC, and the rollout of further commercial AI applications continued for pricing and customer insights. The recently announced acquisition of Woojin Trading, a South Korean specialty distributor of beauty and personal care ingredients, continues Brenntag's growth strategy of bolt-on acquisitions in key markets and expands its presence in South Korea's growing beauty and personal care market. Closing is subject to customary conditions and regulatory approvals and is expected in Q4 2026. Outlook 2026 Brenntag raises its full-year 2026 operating EBITDA outlook to the range of EUR 1,350 million to EUR 1,450 million, based on solid year-to-date performance and a good start to the third quarter supported by recent positive pricing dynamics. Brenntag continues to monitor macroeconomic developments, as risks of demand weakness remain. The company will present a comprehensive update on its medium-term strategy, operating model evolution and long-term value creation framework at its Capital Markets Day on 12 November 2026. Financial Results at a glance - Q2/2026 *Operating gross profit is defined as sales less cost of goods sold. **Unless indicated otherwise, growth rates are on a constant currency basis. ***Brenntag presents operating EBITA / EBITDA before holding charges and special items. Holding charges are certain costs charged between holding companies and operating companies. At Group level, these effects net to zero. Brenntag is also adjusting operating EBITA / EBITDA for income and expenses arising from special items so as to improve comparability in presenting the performance of its business operations over multiple reporting periods and explain it more appropriately. Special items are income and expenses outside ordinary activities that have a special and material effect on the results of operations, such as restructurings. ****Group and Regional Services mainly include the central functions for the entire Group, the regional service functions and the activities with regard to the digitalization of Brenntag's business. Investor presentation. Downloads.
Brenntag has agreed to acquire Woojin Trading Co., a speciality distributor of beauty and personal care ingredients based in Anyang, South Korea. The transaction will strengthen Brenntag's presence in South Korea's influential beauty and personal care market, which is recognised for driving global formulation and product development trends. Founded in 1999, Woojin Trading has developed an extensive network of global suppliers and a growing customer base across Asia. The company operates an in-house laboratory and maintains long-standing relationships with international supply partners. Following the acquisition, customers are expected to benefit from a wider portfolio of ingredients, enhanced formulation expertise and access to Woojin's laboratory capabilities. Financial terms were not disclosed. The transaction is expected to close in the fourth quarter of 2026, subject to customary conditions.
Brenntag: Availability of new BYPHAR Biopharma product range. 24 Jul 2026 Brenntag announces availability of new BYPHAR Biopharma product range - BYPHAR is Brenntag's Biopharma portfolio to simplify raw material selection and regulatory readiness - BYPHAR GMP samples for all products are available and will be released from Brenntag's Pharma GMP Hub Brenntag, the global market leader in chemicals and ingredients distribution, announced the commercial availability of the new Biopharma range BYPHAR. Brenntag announced the three-tier product portfolio supporting biopharmaceutical manufacturers from early R&D through commercial production with a global brand reveal in April. BYPHAR is Brenntag's Biopharma raw material portfolio designed to simplify raw material selection while helping manufacturers meet increasingly stringent regulatory and quality requirements across every stage of biopharmaceutical development and production. Developed specifically for the biopharmaceutical sector, BYPHAR brings together Brenntag's global distribution capabilities, regulatory expertise and technical services into a single, structured offering that enables customers to select raw materials based on application criticality and manufacturing phase. The portfolio supports manufacturers across monoclonal antibodies (mAbs), recombinant proteins, cell and gene therapies, vaccines, nucleic acid production, antibody-drug conjugates (ADCs), biosimilars and diagnostic manufacturing. As the biopharmaceutical industry continues to face increasing regulatory scrutiny, more complex supply chains and growing pressure to accelerate time-to-market, manufacturers require greater confidence in the quality, traceability and compliance of critical raw materials. BYPHAR has been developed to address these challenges through a regulatory-ready portfolio backed by comprehensive documentation, global supply reliability and technical support. "BYPHAR represents a major step forward in how we support our biopharma customers," said Gearoid O'Rourke, Senior Director Biopharma, Brenntag Pharma. "By combining high-quality raw materials and flexibility with global supply reliability and deep regulatory expertise, we are helping customers accelerate development and ensure the highest standards of all manufacturing stages." The BYPHAR portfolio is organized into three product categories aligned with manufacturing risk, allowing manufacturers to select material grades appropriate to their process, risk profile and stage of development: BYPHAR Explore supports research, process development and early-stage manufacturing with non-GMP materials intended for non-critical applications. Products are monograph compliant where applicable and supplied with essential regulatory documentation. BYPHAR Enhance provides GMP-compliant raw materials suitable throughout biopharmaceutical manufacturing. Produced in accordance with IPEC and EXCiPACT guidelines, the portfolio includes comprehensive regulatory-ready documentation to facilitate qualification and validation activities. BYPHAR Excel is designed for critical manufacturing applications, offering LBLE raw materials produced under GMP conditions. Products are multi-compendial where applicable and supported by extensive regulatory documentation to meet the highest standards for quality, compliance and supply assurance. For an intuitive customer journey and for customers to access product specifications, fact sheets and regulatory documentation packages, Brenntag will have a dedicated customer portal available in August. Alongside Brenntag's own-label products, BYPHAR also has co-branded materials from established manufacturing partners including Budenheim, Citribel, K+S and Kerry. The combined portfolio provides access to high-purity phosphates, citric acid and citrates, pharmaceutical-grade salts and acetates, supported by established manufacturing expertise and global supply capabilities. By combining global sourcing, quality systems, technical expertise and regulatory support under a single brand, BYPHAR is intended to help biopharma companies move from transactional procurement towards a more strategic supply partnership. About Brenntag Pharma: Brenntag Pharma is part of Brenntag, the global market leader in chemicals and ingredients distribution. Through its specialist pharma business, the company supplies pharmaceutical and biopharmaceutical manufacturers with high-quality ingredients, regulatory support, technical expertise and value-added services across Europe and international markets. Note: This story has not been edited by The Polymerupdate Editorial team and is auto-generated from a syndicated feed.
Evonik appoints Brenntag as the exclusive European distributor for REXIM(R) GMP-grade amino acids. * Brenntag to lead market development and distribution of REXIM(R) GMP-grade amino acids across most of Europe * Agreement strengthens customer access to high-quality amino acids for pharmaceutical and biopharmaceutical applications * Distributorship expands reach for GMP-grade amino acids in growing markets Evonik REXIM has entered into an agreement with Brenntag Specialties Pharma for the exclusive distribution of its REXIM(R) GMP-grade amino acids across most of Europe. Under the agreement, Brenntag will assume responsibility for market development and distribution in key regions including the DACH region, the UK, France, Benelux, Scandinavia, Central and Eastern Europe, Israel and Turkey. Italy, Ukraine, the Middle East and Africa are excluded from the agreement. "Our agreement with Brenntag significantly strengthens the market reach for our REXIM(R) amino acids," said Thomas Hermann, head of the REXIM product line at Evonik Health Care. "Brenntag's strong regional footprint, deep customer relationships, and extensive experience in the life-science sector make them an ideal partner. Together, we can provide customers with reliable access to high-quality GMP-grade amino acids and support the fast-growing pharmaceutical and biopharmaceutical markets." Evonik REXIM is a leading supplier of high-quality amino acids, with key production capabilities and supply sources located in Europe. The company combines market leadership in fermentation, bioconversion and synthetic-based manufacturing. Its collaboration with Brenntag supports Evonik's ambition for the REXIM(R) portfolio, expanding its presence in key global markets and providing customers with enhanced local service, technical support, and long-term supply security. "Our collaboration with Evonik reflects Brenntag's commitment to bringing high-value pharmaceutical ingredients and solutions closer to our customers," said Joakim Rehné, President Brenntag Pharma EMEA. "By combining Evonik's world-class expertise in GMP-grade amino acids with Brenntag's extensive market presence, technical capabilities, and regulatory know-how, we are uniquely positioned to support the evolving needs of pharmaceutical and biopharmaceutical manufacturers across the region. Together, we are creating a stronger, more reliable supply network that helps accelerate innovation and ensure patient access to critical therapies." Amino acids are fundamental building blocks of life and essential components of proteins, driving key biochemical and metabolic processes. REXIM(R) provides highly purified natural and non-natural amino acids. Their high quality and reliability make them suitable for a wide range of regulated applications, including medical nutrition, active pharmaceutical ingredients (APIs) and excipients, as well as nutrient components for cell culture media used in biopharmaceutical production. As a partner to the pharmaceutical industry, Evonik offers a broad, versatile portfolio of functional excipients, technologies, and contract manufacturing (CDMO) services for oral and parenteral dosage forms. End-to-end CDMO capabilities for small molecule APIs, highly potent APIs and intermediates, as well as high-quality innovative cell culture solutions (e.g., dipeptides, lipids, carbohydrates, surfactants) are also a cornerstone in Evonik's Health Care portfolio. Further information: Evonik: leading beyond chemistry. About custom solutions.